Table 1. Demographic and clinicopathological characteristics of patients with IBC in the BCS and the MT group.
| Characteristic | Surgery type, n (%) | P value | ||
|---|---|---|---|---|
| BCS | MT | All | ||
| No. of patients | 267 (29.5) | 638 (70.5) | 905 (100.0) | |
| Age at diagnosis, years | <0.001 | |||
| <40 | 68 (25.5) | 82 (12.9) | 150 (16.6) | |
| 40–59 | 158 (59.2) | 414 (64.9) | 572 (63.2) | |
| ≥60 | 41 (15.4) | 142 (22.3) | 183 (20.2) | |
| Histologic grade | 0.003 | |||
| 1 | 36 (13.5) | 42 (6.6) | 78 (8.6) | |
| 2 | 170 (63.7) | 427 (66.9) | 597 (66.0) | |
| 3 | 61 (22.8) | 169 (26.5) | 230 (25.4) | |
| Molecular subtypes | 0.198 | |||
| Luminal A-like | 90 (40.2) | 191 (34.2) | 281 (35.9) | |
| Luminal B-like | 79 (35.3) | 219 (39.2) | 298 (38.1) | |
| HER2 overexpression | 17 (7.6) | 63 (11.3) | 80 (10.2) | |
| Basal-like | 38 (17.0) | 85 (15.2) | 123 (15.7) | |
| Stages | <0.001 | |||
| I-II | 253 (94.8) | 519 (81.3) | 772 (85.3) | |
| III-IV | 14 (5.2) | 119 (18.7) | 133 (14.7) | |
| T stages | <0.001 | |||
| Tmic | 9 (3.4) | 12 (1.9) | 21 (2.3) | |
| T1 | 188 (70.4) | 312 (48.9) | 500 (55.2) | |
| T2 | 66 (24.7) | 285 (44.7) | 351 (38.8) | |
| T3/T4 | 4 (1.5) | 29 (4.5) | 33 (3.6) | |
| N stages | <0.001 | |||
| N0 | 212 (79.4) | 379 (59.4) | 591 (65.3) | |
| N1 | 43 (16.1) | 144 (22.6) | 187 (20.7) | |
| N2 | 10 (3.7) | 77 (12.1) | 87 (9.6) | |
| N3 | 2 (0.7) | 38 (6.0) | 40 (4.4) | |
| Nodal surgery | <0.001 | |||
| SLNB | 64 (24.0) | 66 (10.3) | 130 (14.4) | |
| ALND | 189 (70.8) | 567 (88.9) | 756 (83.5) | |
| None | 14 (5.2) | 5 (0.8) | 19 (2.1) | |
| Chemotherapy | 0.605 | |||
| No | 62 (25.6) | 158 (27.7) | 220 (27.1) | |
| Yes | 180 (74.4) | 413 (72.3) | 593 (73.0) | |
| Radiotherapy | <0.001 | |||
| No | 71 (29.6) | 395 (75.8) | 466 (61.2) | |
| Yes | 169 (70.4) | 126 (24.2) | 295 (38.8) | |
| Endocrine therapy | 0.337 | |||
| No | 61 (38.1) | 154 (42.7) | 215 (41.3) | |
| Yes | 99 (61.9) | 207 (57.3) | 306 (58.7) | |
| Mean follow-up time, months (SD) | 127.4 (37.8) | 114.2 (33.2) | 118.1 (35.1) | |
| 10-year BCSS rate (%) | 96.6 | 88.3 | 90.8 | <0.001 |
| I-II | 96.8 | 92.3 | 93.8 | 0.025 |
| III-IV | 91.7 | 70.3 | 72.7 | 0.207 |
| 10-year DFS rate (%) | 87.6 | 83.8 | 84.9 | 0.146 |
| I-II | 89.5 | 88.5 | 88.8 | 0.759 |
| III-IV | 52.2 | 62.6 | 61.1 | 0.832 |
| 10-year LRFS rate (%) | 93.1 | 96.1 | 95.1 | 0.023 |
| I-II | 93.6 | 96.0 | 95.2 | 0.064 |
| III-IV | 83.9 | 96.4 | 94.9 | 0.041 |
IBC, invasive breast cancer; BCS, breast-conserving surgery; MT, mastectomy; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; BCSS, breast cancer-specific survival; DFS, disease-free survival; LRFS, local recurrence-free survival.